Videos

CancerNetwork® sat down with David O’Malley, MD, at the 2021 European Society for Medical Oncology to talk about the OReO trial and how these findings impact what’s already known about PARP inhibitors for the treatment of ovarian cancer.  

David O’Malley, MD, Discusses Findings From the OReO Trial in Ovarian Cancer at 2021 ESMO

Articles

The FDA approved the use of the Pfizer COVID-19 vaccine for patients of a specific age, at risk jobs, or with serious health conditions. 

FDA Approves Additional Pfizer COVID-19 Vaccine Booster For Certain Populations

Patients with relapsed/refractory unresectable or metastatic melanoma may derive benefit from alrizomadlin, which has received a fast track designation from the FDA.

Alrizomadlin Granted FDA Fast Track Designation for Relapsed/Refractory Unresectable or Metastatic Melanoma

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to discuss key data that read out from the OCEAN trial for relapsed/refractory multiple myeloma.  

Fredrik Schjesvold, MD, PhD, Discusses Key Findings From the OCEAN Trial in Relapsed/Refractory Multiple Myeloma

Results from the phase 3 eXalt3 study indicated that ensartinib led to a longer progression-free survival and intracranial response rate compared with crizotinib for patients with ALK-positive non-small cell lung cancer. 

Ensartinib Yields Superior Efficacy Over Crizotinib for ALK-Positive Non–Small Cell Lung Cancer

CancerNetwork® spoke with Michael Schweizer, MD, at the 2021 ESMO Congress about his research into the combination of olaparib plus bipolar androgen therapy for patients with castration-resistant prostate cancer.

Expert Discusses Bipolar Androgen Therapy Plus PARP Inhibition for Castration-Resistant Prostate Cancer

A phase 2 trial did not find a significant benefit to progression-free survival with regorafenib in patients with advanced or metastatic chrodoma.


Progression-Free Survival Not Seen With Regorafenib in Advanced Chordoma 

Patients with chronic graft-versus-host disease who have received prior therapy can now receive treatment with ruxolitinib following its approval by the FDA.

FDA Approves Ruxolitinib for the Treatment of Previously Treated Chronic Graft-Versus-Host Disease

Findings from the PACIFIC-R trial indicated that the real-world progression-free survival benefit of durvalumab was higher vs the median progression-free survival reported in the durvalumab arm of the phase 3 PACIFIC trial in unresectable stage III non–small cell lung cancer.


Durvalumab Demonstrates Real-World PFS Benefit In Unresectable Stage III NSCLC

Results from the phase 3 NINJA trial indicated that chemotherapy agents such as gemcitabine or pegylated liposomal doxorubicin yielded better survival outcomes vs nivolumab among patients with platinum-resistant ovarian cancer.

All News